Anthony Culverwell
Directeur/Membre du Conseil chez TC BIOPHARM (HOLDINGS) PLC
Fortune : - $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Denise Carter | F | 55 | 6 ans | |
Michael Myers | M | 62 | 6 ans | |
Gordon Dunn | M | 60 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 8 ans |
Arlene Morris | F | 72 | 2 ans | |
Michael Sember | M | - | 3 ans | |
Dennis Langer | M | 73 | 3 ans | |
Natalie Leong | F | 39 | 3 ans | |
Andrew Richard Boyce | M | 62 |
Atlantic Healthcare Plc
Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | 12 ans |
Bryan Kobel | M | 44 | 3 ans | |
Edward Niemczyk | M | 44 | 2 ans | |
Martin Thorp | M | 72 | 9 ans | |
Mark Bonyhadi | M | 70 | 2 ans | |
Joseph Cooper | M | 66 | 3 ans | |
Tony Brampton | M | 66 |
Sudbrook Associates LLP
| - |
Wayne Fox | M | 77 |
Safeguard Biosystems Holdings Ltd.
Safeguard Biosystems Holdings Ltd. Medical SpecialtiesHealth Technology Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom. | - |
Howard Mark Sherman | M | 66 |
Safeguard Biosystems Holdings Ltd.
Safeguard Biosystems Holdings Ltd. Medical SpecialtiesHealth Technology Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom. | 18 ans |
George Richard Aaron | M | 72 |
Safeguard Biosystems Holdings Ltd.
Safeguard Biosystems Holdings Ltd. Medical SpecialtiesHealth Technology Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom. | - |
Arthur Harold Rubenstein | M | 87 |
Safeguard Biosystems Holdings Ltd.
Safeguard Biosystems Holdings Ltd. Medical SpecialtiesHealth Technology Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom. | - |
Randeep Singh Grewal | M | 57 |
Hox Therapeutics Ltd.
Hox Therapeutics Ltd. BiotechnologyHealth Technology Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
David Brennan | M | 70 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | - |
Richard Fante | M | - |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 6 ans |
Shumeet Banerji | M | 63 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | - |
Jonathan Symonds | M | 66 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 3 ans |
Michael Leek | M | 64 | 10 ans | |
Joe Wiley | M | 53 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | - |
Angela Scott | F | 60 | 10 ans | |
Ray Stafford | M | 77 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 7 ans |
Anthony Zook | M | 63 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 5 ans |
Jose Carmona | M | 51 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 2 ans |
Stephen Joyce | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Alain Munoz | M | 75 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Tony H. Wild | M | 75 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | 1 ans |
Charles F. Katzer | M | 74 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | - |
Cathal Friel | M | 59 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 13 ans |
Jordi Casals | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Derval O'Carroll | F | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Patrick Jordan | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Stephen Wills | M | 67 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 4 ans |
John McEvoy | M | 37 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Julie Eastwood | F | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Helen Phillips | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Sebastian Wanless | M | 68 | 2 ans | |
David Allmond | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 ans |
James Tursi | M | 59 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | - |
Michele Bellandi | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
George Hampton | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Markus Ziener | M | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 ans |
Donald Stern | M | 78 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Kieran Rooney | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Mark Sumeray | M | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 6 ans |
Patrick Volkert Vink | M | 60 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
Harry Thomas Stratford | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 ans |
David Laurence George Danson | M | 79 |
Safeguard Biosystems Holdings Ltd.
Safeguard Biosystems Holdings Ltd. Medical SpecialtiesHealth Technology Safeguard Biosystems Holdings Ltd. engages in the development, manufacture, and sales of diagnostic tests for human and animal health; and food safety products. The company was founded on May 11, 2006 and is headquartered in London, the United Kingdom. | - |
Lesley Russell | M | 63 | 1 ans | |
Bree Harlin | M | - | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 37 | 67,27% |
Etats-Unis | 16 | 29,09% |
Irlande | 11 | 20,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Anthony Culverwell
- Réseau Personnel